Certara Investor Presentation Deck

Blue chip customer base spanning large biopharma and biotech Eisai Abbott Pfizer ARVINAS (Incyte) Otsuka CHEST Select Customers astellas gsk Lundbeck SANOFI AstraZeneca biohaven clarus GALDERMA Opharmaceuticals THERAPEUTICS © Copyright 2022 Certara, Inc. All rights reserved. Lilly Medicines Development for Global Health SHIONOGI INC. Sumitomo Dainippon VERTEX Pharma Mitsubishi Tanabe Pharma GRUNENTHAL Biogen MERCK TAISHO PHARMACEUTICAL NEKTAR idorsia ono ucb Number of FDA Approvals Since 2014 Orphan designation Oncology Infectious disease Neurology Hematology Dermatology Cardiology Gastroenterology Pulmonary Diabetes Migraine Psychiatry Sleep disorders Bone Other 0 20 90% of novel drug approvals were achieved by our customers 40 60 80 Number of Drug Approvals *Excludes diagnostics Orphan designation applies across therapeutic areas We have more than 2,000 customers worldwide across 62 countries, including 38 of the top 40 biopharmaceutical companies by R&D spend in 2020 100 9 120 140 CERTARA

View entire presentation